NCT02214628View on ClinicalTrials.gov

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

PHASE2TerminatedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Age-related Macular Degeneration
Interventions
DRUG

Fovista® (anti-PDGF BB) plus anti-VEGF

Trial Locations (13)

29456

Ladson

30909

Augusta

45242

Cincinnati

49202

Jackson

55435

Minneapolis

60452

Oak Forest

79606

Abilene

85014

Phoenix

90211

Beverly Hills

92705

Santa Ana

95819

Sacramento

95841

Sacramento

02114

Boston

Sponsors
All Listed Sponsors
lead

Ophthotech Corporation

INDUSTRY

NCT02214628 - Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD | Biotech Hunter | Biotech Hunter